Phathom Pharmaceuticals (id:8015 PHAT)
9.34 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 2:06:54 PM)
Exchange closed, opens in 19 hours 23 minutes
3.55 USD (3.55%)
6.38 USD (6.38%)
-41.07 USD (-41.07%)
-13.60 USD (-13.60%)
26.39 USD (26.39%)
-59.76 USD (-59.76%)
-58.49 USD (-58.49%)
About Phathom Pharmaceuticals
Market Capitalization 607.88M
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
| Headquarters (address) |
100 Campus Drive Florham Park 07932 NJ United States |
| Phone | 877 742 8466 |
| Website | https://www.phathompharma.com |
| Employees | 452 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | PHAT |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 6.06 - 19.71 |
| Market Capitalization | 607.88M |
| P/E trailing | -2.38 |
| P/E forward | -2.22 |
| Price/Sale | 23.14 |
| Price/Book | -3.23 |
| Beta | 0.718 |
| EPS | -5.74 |
| EPS United States (ID:6, base:3402) | 24.22 |